Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction
Authors
Keywords
-
Journal
CIRCULATION
Volume 142, Issue 13, Pages 1236-1245
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2020-08-17
DOI
10.1161/circulationaha.120.047643
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction
- (2019) Wendy McCallum et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
- (2019) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Sacubitril/Valsartan Versus Irbesartan in Patients with Chronic Kidney Disease: A Randomised Double-Blind Trial
- (2018) Richard Haynes et al. CIRCULATION
- Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial
- (2018) Scott D. Solomon et al. Circulation-Heart Failure
- LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease
- (2018) Yasunori Suematsu et al. JOURNAL OF CARDIAC FAILURE
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure
- (2018) Kevin Damman et al. JACC-Heart Failure
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Worsening Renal Function and Outcome in Heart Failure Patients With Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment
- (2014) Kevin Damman et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Spironolactone for Heart Failure with Preserved Ejection Fraction
- (2014) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
- (2014) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis
- (2013) K. Damman et al. EUROPEAN HEART JOURNAL
- Increased Proximal Arterial Stiffness and Cardiac Response With Moderate Exercise in Patients With Heart Failure and Preserved Ejection Fraction
- (2012) Lamia Tartière-Kesri et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
- (2012) Scott D Solomon et al. LANCET
- Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction
- (2011) Patrick Rossignol et al. CIRCULATION
- Efficacy and Safety of Carvedilol in Treatment of Heart Failure with Chronic Kidney Disease
- (2010) Ravinder K. Wali et al. Circulation-Heart Failure
- Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to Severe Heart Failure
- (2009) Inder S. Anand et al. CIRCULATION
- Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)
- (2009) Jessie Gu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The Pathophysiology of Heart Failure With Normal Ejection Fraction
- (2009) Yu Ting Tan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction
- (2008) Barry M. Massie et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started